Aventis Pharma Deutschland, Gmbh

Piramal Life Sciences Limited

Nicholas Piramal India Limited

Triptikumar Mukhopadhyay

Swati Ajay Piramal

Ravi Gajanan Bhat

Kenia Jayvanti

Erra Koteswara Satya Vijaya Kumar

Vidya Narayan Acharya

E S Sreekumar

The present invention relates to the use of standardized extract ofas an immunoadjuvant in the treatment of renal disorders such as nephrotic syndrome and chronic recurrent urinary tract infections, both complicated and uncomplicated. The present invention also relates to pharmaceutical compositions comprising the standardized extract of The present invention further relates to a method of treatment of renal disorders such as recurrent urinary tract infection particularly occurring due to relapsingand other gram negative infections and to a method of treatment of nephrotic syndrome using standardized extract ofas an immunoadjuvant in conjunction with conventional therapy.

Herbal extract for renal disorders

The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.

Crystalline glucosamine sulfate metal salts and processes for preparing the same

The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which consists of a single step selective reduction of C4-htyr (homotyrosine) hydroxyl group of echinocandins to their monodeoxy analogues under neutral conditions without prior protection/deprotection of the equally facile C5-Orn (ornithine) hydroxyl group and purification of the monodeoxy compound from the crude reaction mixture.

Process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues

Growing community of inventors

Mumbai, India

Triptikumar Mukhopadhyay